# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Billie Holiday (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML010-SYN-TD
- Date: 1948-10-19
- Fictional facility: St. Posthumous Health Center
- Fictional author: Constance Mayfield, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-month recovery, alcohol, liver, and mood review. **S**

## History of present illness

Ms. Holiday returns six months after starting buprenorphine. She has taken 16 mg every day since the return to use before the three-month visit and has used no heroin or other opioids for three months. The early refill and travel letter worked on her last tour. She drinks one drink on some performance nights and none otherwise. Her dental abscess was drained by the dentist the week of her sick visit, and the tooth has since had root canal treatment; she finished the amoxicillin and needed the pain tablets for only three days. She sleeps better and enjoys singing again. She sees her counselor weekly and her peer recovery coach every two weeks. **S**

| Element | Detail |
|---|---|
| Opioid use | None for three months |
| Buprenorphine | 16 mg daily, no gaps |
| Alcohol | One drink on some performance nights |
| Tooth | Abscess drained; root canal completed; no pain |
| Mood | PHQ-9 4 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy better; weight up 1.6 kg |
| Ears, nose, mouth, and throat | Negative | No tooth pain or swelling |
| Psychiatric | Negative | Mood good; PHQ-9 score 4; no thoughts of suicide or self-harm |

3 systems reviewed. **S**

## Current medications

- Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily **S**
- Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils; call 911 **S**
- Acamprosate 333 mg delayed-release oral tablet, two tablets (666 mg) by mouth three times daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 116/74 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 69 kg; BMI 25.3 kg/m². All vital signs are synthetic.

Hemoglobin: 12.9 g/dL; MCV: 95 fL; Platelets: 248 10*3/uL; AST: 30 U/L; ALT: 26 U/L; GGT: 34 U/L; Phosphatidylethanol (PEth): 22 ng/mL (high); PHQ-9: 4. All results are synthetic.

## Change since baseline

- Hemoglobin: 12.4 g/dL at baseline, 12.9 g/dL at this visit **S**
- MCV: 101 fL (high) at baseline, 95 fL at this visit **S**
- Platelets: 236 10*3/uL at baseline, 248 10*3/uL at this visit **S**
- AST: 52 U/L (high) at baseline, 30 U/L at this visit **S**
- ALT: 38 U/L at baseline, 26 U/L at this visit **S**
- GGT: 84 U/L (high) at baseline, 34 U/L at this visit **S**
- Phosphatidylethanol (PEth): 312 ng/mL (high) at baseline, 22 ng/mL (high) at this visit **S**
- PHQ-9: 9 at baseline, 4 at this visit **S**

## Immunizations given today

- Hepatitis A vaccine, adult, dose 2 of 2 **S**
- Influenza vaccine, 1948-1949 season **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 116/74, pulse 72 |
| Mouth | Treated lower right molar; no swelling |
| Abdomen | Soft; no liver enlargement |
| Psychiatric | Bright and engaged; no signs of intoxication or withdrawal |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Opioid use disorder on buprenorphine** (F11.20). Three months without opioid use and six months of continuous treatment, including the return to use, which she came through safely. Urine test shows buprenorphine only. Safety reviewed: no thoughts of suicide or self-harm. **S**
   - Continue buprenorphine with naloxone 16 mg daily; visits every month.
   - Naloxone and test strips checked; both in date.
2. **Alcohol use disorder on acamprosate** (F10.20). PEth 22 ng/mL, from 312 at intake: light, occasional drinking, as she chose. AST 30, ALT 26, GGT 34 U/L, now normal. MCV 95, back to normal. FIB-4 0.78 (age 33, AST 30, ALT 26, platelets 248), low risk. **S**
   - Continue acamprosate for at least six more months, then review.
   - Stop thiamine now that drinking is light.
   - Liver tests and FIB-4 yearly.
3. **Periapical abscess** (K04.7). Resolved after drainage and root canal treatment. **S**
   - Dental review every six months.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Buprenorphine dose, adherence, cravings, withdrawal, and side effects | Every visit | Completed today | 16 mg daily without gaps; no cravings this month |
| Self-management | Visit frequency | Every 1 to 2 weeks in the first month after starting, then every 2 to 4 weeks until stable | Completed today | Stable; monthly visits from now |
| Laboratory | Urine drug testing, including fentanyl, explained as part of care rather than as a test of trust | At the start, then about monthly early in treatment and as needed | Completed today | Buprenorphine and norbuprenorphine only |
| Medication safety | Prescription drug monitoring program check | Before each buprenorphine prescription | Completed today | Only the dental prescriptions from the sick visit, which were not opioids |
| Medication safety | Naloxone at home and in her bag, and a trained companion | At the start; check and replace at each visit | Completed today | In date at home and in her bag |
| Medication safety | Prescription continuity on tour (pharmacy, prior authorization, travel letter) | Before each tour | Completed today | Early fill and travel letter worked on the last tour |
| Self-management | Counseling and peer recovery support | Offered to everyone; not a condition of medication | Completed today | Counseling weekly; peer coach every two weeks |
| Self-management | Oral care on sublingual buprenorphine | At the start and yearly | Completed today | Abscess treated; dental review every six months |
| Survey | Drinking and PEth | PEth at intake and at each check while drinking continues; AUDIT-C yearly | Completed today | PEth 22 ng/mL; AUDIT-C 3 at the preventive visit |
| Medication safety | Acamprosate adherence and kidney function | Kidney function before starting; adherence every visit | Completed today | Taking all three doses |
| Medication safety | Thiamine | While drinking heavily | Completed today | Stopped today; drinking is light |
| Laboratory | Liver tests (AST, ALT, GGT, albumin, bilirubin) | At intake, then every 1 to 3 months while drinking is heavy, and yearly | Completed today | AST 30, ALT 26, GGT 34 U/L, normal |
| Laboratory | Blood count | At intake and with liver tests while drinking | Completed today | Hemoglobin 12.9 g/dL, MCV 95 fL (from 101), platelets 248 |
| Laboratory | FIB-4 fibrosis score | At intake; repeat in 6 to 12 months with ongoing drinking, and every 1 to 2 years | Completed today | 0.78, low risk; repeat yearly |
| Imaging | Vibration-controlled transient elastography | If FIB-4 is 1.3 or higher | Not indicated | FIB-4 below 1.3 |
| Laboratory | Hepatitis C, hepatitis B, and HIV testing | At entry to care, then yearly while any drug use continues | Due | Nonreactive at intake; repeat at the intake anniversary |
| Self-management | Hepatitis A and B vaccines | Hepatitis B two doses 4 weeks apart; hepatitis A two doses 6 months apart | Completed today | Hepatitis A dose 2 given today; both series complete |
| Self-management | Influenza vaccine | Each autumn | Completed today | Given today |
| Survey | Depression screen (PHQ-9) | At intake and at each recovery visit while symptoms are present | Completed today | PHQ-9 4, from 9 at intake and 11 at three months |
| Survey | Suicide and overdose risk review, safety plan, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; the 988 Suicide & Crisis Lifeline in her phone |

## Goal progress

- Stay on buprenorphine without interruption through six months, including through any return to use. Outcome by 1948-10-19: Taking buprenorphine 16 mg daily at six months; a three-day gap during a tour was followed by a brief return to use and an immediate restart, with no overdose. **S**
- Naloxone at home and in her bag, and a friend trained to use it, by the one-week visit. Outcome by 1948-04-27: Two naloxone two-packs dispensed; her friend trained. **S**
- Reduce drinking to PEth below 20 ng/mL, or to the level she chooses, by six months. Outcome by 1948-10-19: PEth 22 ng/mL from 312; occasional light drinking, which she chose. **S**
- Hepatitis A and B vaccine series completed by six months. Outcome by 1948-10-19: Hepatitis B doses at intake and five weeks; hepatitis A doses at intake and six months. **S**
- PHQ-9 score below 5 by six months. Outcome by 1948-10-19: PHQ-9 4. **S**

## Medication changes

- Stopped: Thiamine 100 mg oral tablet, one tablet by mouth daily **S**

## Guideline basis

- The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020), American Society of Addiction Medicine (Journal of Addiction Medicine)
- Treatment Options for Substance Use Disorder (medications for opioid and alcohol use disorders) (2026), Substance Abuse and Mental Health Services Administration
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019), American Association for the Study of Liver Diseases (Hepatology)
- AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis (2025), American Association for the Study of Liver Diseases (Hepatology)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Monthly buprenorphine visits. Counseling weekly. Liver tests, FIB-4, and infection screening at one year. **S**

